About Broad street alerts
Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our members in December 2015 alone.
Big opportunity in Small Cap’s during an overall market decline.
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100% in gains for our members.
December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of 19% for our members.
December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business. We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “alerts” to the phone number 25827 from your cell phone.
Report- GeoVax Labs, Inc. (OTCQB: GOVX)
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Virus Ankara – Virus-Like Particle (MVA-VLP) vaccine platform. The Company also recently began a program to evaluate the use of its MVA-VLP platform in cancer immunotherapy. GeoVax’s most advanced development programs are focused on vaccines against HIV and hemorrhagic fever viruses (Ebola, Marburg, and Lassa).
On February 1, 2016, the World Health Organization (WHO) designated the Zika virus and its suspected complications in newborns an international public health emergency. The Zika epidemic, currently in 24 countries in the Americas, is transmitted by the Aedes mosquito and is expected by the WHO to reach most of the Western Hemisphere, infecting up to 4 million people by year’s end. The Centers for Disease Control and Prevention (CDC) has issued a travel advisory for people traveling to regions within the Zika virus outbreak, which include popular vacation destinations. Brazil, the site of the 2016 Summer Olympic Games, is included in the advisory. More than 30 cases have been reported in the United States, imported by travelers visiting affected regions.
Zika virus is a member of the Flaviviridae family, which includes dengue fever, yellow fever, Japanese encephalitis, tick-borne encephalitis, and West Nile viruses. There is an alarming association between Zika infections and severe birth defects, including over 4000 cases of microcephaly in Brazil since fall 2015, 270 of which show confirmed evidence of infection. Microcephaly is a congenital condition marked by an abnormally small head and incomplete brain development. A potential link to Zika infection is also suspected in adults diagnosed with Guillain-Barré syndrome, a rare autoimmune disorder that can cause paralysis.
Other than mosquito control, no approved preventive or therapeutic products are currently available to fight Zika infections. Public health officials recommend avoiding exposure to Zika, delaying pregnancy, and following basic supportive care after infection. A vaccine is urgently needed to prevent a Zika pandemic.
GOVX has begun a program to develop a vaccine for the prevention of Zika virus infections using its novel MVA-VLP vaccine platform. The company believes that it can rapidly advance a vaccine candidate to human clinical testing. GeoVax’s Senior Vice President of Research and Development, Farshad Guirakhoo, PhD, will lead the company’s effort in developing a Zika virus vaccine. Dr. Guirakhoo played pivotal roles in the development and licensure of human vaccines against Flaviviruses including dengue and Japanese encephalitis. His extensive experience and expertise with Flavivirus vaccine development gives the company an advantage over competitors and will shorten the time until a Zika vaccine can be brought to market by GeoVax and its partners. GeoVax has also entered into a Collaborative Research Agreement with the University of Georgia to speed development of the vaccine.
Broad street alerts has compensated the author of this report (LIX Research) up to two hundred fifty dollars for the redistribution rights for a period of 30 days. Broad street alerts and parent company Small cap specialists LLC have not been compensated in any way for this post.